North China Pharmaceutical Co (600812.SS) Stock Price

North China Pharmaceutical Co Price

SSE·CLOSED
4.23
​
Market closed

Over the last 19 years North China Pharmaceutical Co grew revenue by 4.5% annually, reaching 9.24 B CNY. Earnings per share have grown at 3.4% per year over the last 18 years. For North China Pharmaceutical Co, the net margin of 2.0% is up versus 0.2% a few years ago. At today's price the dividend yield works out to roughly 0.71%. The payout ratio is around 28% of earnings.

North China Pharmaceutical Co stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

North China Pharmaceutical Co business model & stock analysis

North China Pharmaceutical Co., Ltd. generates revenue through the manufacture and sale of antibiotics, vitamins, and pharmaceutical products. The company focuses on research and development, production, and sales of chemical raw materials, chemical preparations, biological preparations, pharmaceutical intermediates, and nutraceuticals. Its product portfolio includes infective drugs, biotech drugs, cardio cerebrovascular drugs, nephropathy and immunomodulatory drugs, cancer therapeutic drugs, and vitamins. The firm distributes these products domestically and internationally, with pharmaceutical logistics services supporting its supply chain. The company's primary customers are domestic and international markets seeking pharmaceutical solutions. It serves segments including hospitals, clinics, and healthcare providers through its extensive product range. North China Pharmaceutical leverages its expertise in chemical and biological preparations to address diverse medical needs, from infectious diseases to cancer treatments. The firm's logistics business ensures efficient distribution across its target markets. Revenue streams are derived from the sale of chemical raw materials, pharmaceutical intermediates, and finished products such as antibiotics and vitamins. The company’s focus on biotech and cardio cerebrovascular drugs positions it within key therapeutic areas. Its international distribution network expands market reach, while its domestic presence solidifies its role as a leading pharmaceutical provider in China.

Frequently asked questions about North China Pharmaceutical Co

6 analysts currently rate the North China Pharmaceutical Co stock: 0 recommend buying, 3 holding and 3 selling. For 2026, analysts expect North China Pharmaceutical Co to generate revenue of 11.09 B CNY and earnings per share of 0.16 CNY.

Converted at the current exchange rate, the North China Pharmaceutical Co share trades at 0.58 EUR (4.23 CNY).

The North China Pharmaceutical Co share (600812.SS) is listed on 1 stock exchanges, including: Shanghai (600812.SS).

The expected revenue of North China Pharmaceutical Co is 11.09 B CNY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of North China Pharmaceutical Co is 274.52 M CNY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of North China Pharmaceutical Co is currently 26.44. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the North China Pharmaceutical Co stock.

The price-to-sales ratio (P/S) of North China Pharmaceutical Co is currently 0.65. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the North China Pharmaceutical Co stock.

The Eulerpool Quality Score for North China Pharmaceutical Co is 4/10.

The ISIN of North China Pharmaceutical Co is CNE000000D16. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of North China Pharmaceutical Co is 600812.SS. The ticker symbol is used to trade North China Pharmaceutical Co shares on the stock exchange.

Fair ValueTerminal
4.10 CNY
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
843,832.45 CNY
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website ncpc.com
Country
Currency
CNY
Initial public offering
Jan 14, 1994
ISIN
CNE000000D16
Cusip
Y6408H100
Market capitalization
7.26 B CNYMid Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
26.44
P/Ee 2027
—
P/S
P/Se
0.65
EV/EBIT
11.41
P/B Ratio
1.32
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
2.48 %
Dividend
Dividend yield
0.71 %
Est. Dividend Yield
0.71 %
Payout Ratio
28.12 %
Dividend growth Ø5Y
—
Dividend payments per year
1
Dividend paid since
2 years
Dividend not reduced since
2 years
Dividend increased since
2 years
Dividend withholding tax
10.00 %
Last updated Nov 21, 2026, 8:52 PM

North China Pharmaceutical Co Peer Group

North China Pharmaceutical Co Ticker

SHH · 600812.SS

North China Pharmaceutical Co FIGI

600812:CH · BBG000BKC6G8600812:CG · BBG000BKC6P8600812:C1 · BBG01FRB06F1